These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Endothelin receptor antagonists in pulmonary arterial hypertension]. Tokgöz HC; Can MM; Kaymaz C Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750 [TBL] [Abstract][Full Text] [Related]
5. Endothelin receptor antagonists -- their role in pulmonary medicine. Boniface S; Reynaud-Gaubert M Rev Mal Respir; 2011 Oct; 28(8):e94-e107. PubMed ID: 22099418 [TBL] [Abstract][Full Text] [Related]
6. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Raja SG Cardiovasc Ther; 2010 Oct; 28(5):e65-71. PubMed ID: 20406243 [TBL] [Abstract][Full Text] [Related]
7. Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism. Trow TK; Taichman DB Respir Med; 2009 Jul; 103(7):951-62. PubMed ID: 19304472 [TBL] [Abstract][Full Text] [Related]
8. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Abman SH Annu Rev Med; 2009; 60():13-23. PubMed ID: 18764741 [TBL] [Abstract][Full Text] [Related]
9. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. Yao A J Cardiol; 2012 Nov; 60(5):344-9. PubMed ID: 23068290 [TBL] [Abstract][Full Text] [Related]
10. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists. Madonna R; Cocco N; De Caterina R Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170 [TBL] [Abstract][Full Text] [Related]
12. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Davie NJ; Schermuly RT; Weissmann N; Grimminger F; Ghofrani HA Eur J Clin Invest; 2009 Jun; 39 Suppl 2():38-49. PubMed ID: 19335746 [TBL] [Abstract][Full Text] [Related]
13. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Hachulla E; Coghlan JG Ann Rheum Dis; 2004 Sep; 63(9):1009-14. PubMed ID: 15308510 [TBL] [Abstract][Full Text] [Related]
14. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension. Clozel M Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881 [TBL] [Abstract][Full Text] [Related]
15. Sarcoidosis-associated pulmonary hypertension: assessment and management. Palmero V; Sulica R Semin Respir Crit Care Med; 2010 Aug; 31(4):494-500. PubMed ID: 20665399 [TBL] [Abstract][Full Text] [Related]
16. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Raja SG Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702 [TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639 [TBL] [Abstract][Full Text] [Related]
19. [Endothelin: From discovery to pharmacotherapeutic innovations]. Richard V Presse Med; 2014; 43(7-8):742-55. PubMed ID: 24797866 [TBL] [Abstract][Full Text] [Related]
20. [Update: Current clinical developments in pulmonary hypertension]. Dumitrescu D; Ghofrani HA; Grimminger F; Hoeper MM; Rosenkranz S Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S160-3. PubMed ID: 19718605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]